Taken together, Meplazumab can competitively block the binding between spike and CD147, thus effectively treat COVID-19 by reducing viral entry and suppressing CyPA-mediated cytokines overexpression (Fig. 6i), supportive of our exploratory phase II clinical trial results.37 Therefore, CD147 is a promising target for the treatment of COVID-19 caused by SARS-CoV-2 and its variants. Here, BSG is linked to COVID-19.